Current Urology Reports

, 20:47 | Cite as

First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature

  • Daniele Amparore
  • Sabrina De Cillis
  • Gabriele Volpi
  • Enrico Checcucci
  • Matteo Manfredi
  • Ivano Morra
  • Michele Di Dio
  • Cristian Fiori
  • Francesco PorpigliaEmail author
  • on behalf of ESUT Group
Part of the following topical collections:
  1. Topical Collection on Benign Prostatic Hyperplasia



In the last decade, there has been a growing interest in minimally invasive treatment for benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS). In this field, one of the options currently available is the temporary implantable nitinol device (iTIND) (Medi-Tate®; Medi-Tate Ltd., Or Akiva, Israel).

Purpose of the Work

To review the recent data available in the literature regarding the role of the first-generation (TIND) and second-generation (iTIND) devices for the management of BPH with LUTS, especially focusing on follow-up of functional outcomes.

Evidence Acquisition

PubMed, Embase, and the Cochrane Central Register of Controlled Trials were screened for clinical trials on this topic.

Evidence Synthesis

Literature evidences regarding implantation of TIND and iTIND for PBH with LUTS are limited. There are only three studies available, one with a medium-term follow-up. The results of these studies suggested that both the TIND and iTIND implantations are safe, effective, and well-tolerated procedures, allowing spare ejaculation in sexually active patients.


Current evidences emphasize that the temporary implantable nitinol devices are promising alternatives to the standard minimally invasive surgical options for BPH-related LUTS. Further studies are needed to confirm the effectiveness over a long-term follow-up.


BPH LUTS iTIND Minimally invasive techniques Nitinol Urethral implantable device 


Compliance with Ethical Standards

Conflict of Interest

Daniele Amparore, Sabrina De Cillis, Gabriele Volpi, Enrico Checcucci, Matteo Manfredi, Ivano Morra, Michele Di Dio, Cristian Fiori, and Francesco Porpiglia each declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22(Suppl 1):1–6.PubMedGoogle Scholar
  2. 2.
    Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph Project. Eur Urol. 2003;44:539–45.CrossRefGoogle Scholar
  3. 3.
    •• Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, et al. Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2017;71(4):570–81. A complete resign of the available medical treatment of BPH. CrossRefGoogle Scholar
  4. 4.
    Presicce F, De Nunzio C, Gacci M, et al. The influence of the medical treatment of LUTS on benign prostatic hyperplasia surgery: do we operate too late. Minerva Urol Nefrol. 2017;69:242–52.PubMedGoogle Scholar
  5. 5.
    Marszalek M, Ponholzer A, Pusman M, Berger I, Madersbacher S. Transurethral resection of the prostate. Eur Urol Suppl. 2009;8:504–12.CrossRefGoogle Scholar
  6. 6.
    Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–40.CrossRefGoogle Scholar
  7. 7.
    DE Nunzio C, Lombardo R, Nacchia A, Deroma M, Alkhatatbeh H, Brassetti A, et al. Young academic urologist benign prostatic obstruction nomogram predicts clinical outcome in patients treated with transurethral resection of prostate: an Italian cohort study. Minerva Urol Nefrol. 2017.
  8. 8.
    Geavlete P. Is classical transurethral resection of the prostate, the gold standard endoscopic treatment for benign prostate hyperplasia, in real danger of being replaced? Eur Urol. 2010;58:356–9.CrossRefGoogle Scholar
  9. 9.
    Rieken M, Presicce F, Autorino R, DE Nunzio C. Clinical significance of intravesical prostatic protrusion in the management of benign prostatic enlargement: a systematic review and critical analysis of current evidence. Minerva Urol Nefrol. 2017;69(6):548–55.PubMedGoogle Scholar
  10. 10.
    Brassetti A, De Nunzio C, Delongchamps NB, Fiori C, Porpiglia F, Tubaro A. Green light vaporization of the prostate: is it an adult technique? Minerva Urol Nefrol. 2017;69:109–18.PubMedGoogle Scholar
  11. 11.
    Gravas S, Bachmann A, Reich O, Roehrborn CG, Gilling PJ, De La Rosette J. Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int. 2011;107:1030–43.CrossRefGoogle Scholar
  12. 12.
    Naspro R, Gomez Sancha F, Manica M, Meneghini A, Ahyai S, Aho T, et al. From “gold standard” resection to reproducible “future standard” endoscopic enucleation of the prostate: what we know about anatomical enucleation. Minerva Urol Nefrol. 2017;69(5):446–58.PubMedGoogle Scholar
  13. 13.
    Helo S, Holland B, McVary KT. Convective radiofrequency water vapor thermal therapy with Rezūm system. Curr Urol Rep. 2017;18(10):78.CrossRefGoogle Scholar
  14. 14.
    Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–109.CrossRefGoogle Scholar
  15. 15.
    Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int. 2017;119:767–75.CrossRefGoogle Scholar
  16. 16.
    •• Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int. 2015;116(2):278–87. Literature showing clinical results of the temporary implantable nitinol device. CrossRefGoogle Scholar
  17. 17.
    •• Porpiglia F, Fiori C, Amparore D, Kadner G, Manit A, Valerio M, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int. 2018;123:1061–9. Literature showing clinical results of the temporary implantable nitinol device. CrossRefPubMedGoogle Scholar
  18. 18.
    Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010;58(3):384–97.CrossRefGoogle Scholar
  19. 19.
    Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol. 2017;72(6):986–97.CrossRefGoogle Scholar
  20. 20.
    Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.CrossRefGoogle Scholar
  21. 21.
    •• Porpiglia F, Fiori C, Bertolo R, Giordano A, Checcucci E, Garrou D, et al. Three-year follow-up of temporary implantable nitinol device (TIND®) implantation for the treatment of benign prostatic obstruction. BJU Int. 2018;122:106–12. Literature showing clinical results of the temporary implantable nitinol device. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Daniele Amparore
    • 1
  • Sabrina De Cillis
    • 1
  • Gabriele Volpi
    • 1
  • Enrico Checcucci
    • 1
  • Matteo Manfredi
    • 1
  • Ivano Morra
    • 1
  • Michele Di Dio
    • 1
  • Cristian Fiori
    • 1
  • Francesco Porpiglia
    • 1
    Email author
  • on behalf of ESUT Group
  1. 1.Division of Urology, Department Of Oncology, School of Medicine, University of TurinSan Luigi HospitalTurinItaly

Personalised recommendations